Collaborating for novel solutions (CNS) Summit 2025
CNS Summit 2025, taking place November 2–5 at Encore Boston Harbor, is a premier gathering for leaders in life sciences, pharma, and biotech focused on advancing innovation in drug development and neuroscience. The event brings together over a thousand executives, researchers, investors, and regulators for four days of keynotes, spotlight talks, networking sessions, and an Innovation Showcase highlighting breakthroughs in AI, digital medicine, decentralized trials, and real-world evidence. More than a traditional conference, CNS Summit 2025 fosters a collaborative community dedicated to shaping the future of clinical research and healthcare innovation.
Clario is presenting a poster on “Site Rater Performance as a Function of Scale Experience, Indication Experience, and Educational Level in MDD”.
Session information:
Session 1
Date: Monday, November 3, 2025
Time: 5:00 pm – 7:00 pm ET
Session 2
Date: Tuesday, November 4, 2025
Time: 5:00 pm – 7:00 pm ET
Abstract:
This study evaluated the predictors of site rater performance in major depressive disorder (MDD) clinical trials by analyzing the education level, depression (indication) experience, and specific scale (MADRS) experience of 217 raters. The results showed that raters with greater experience using the MADRS scale demonstrated significantly higher assessment quality, scoring accuracy, and fewer discrepancies compared to expert reviewers, with scale experience emerging as the strongest predictor of rater performance. Indication experience also contributed to improved scoring accuracy and reduced discrepancies, while educational level was less influential. Overall, the findings highlight that scale experience, followed by indication experience, are the most important factors in ensuring high-quality rater performance in MDD trials.
Speaker
Bill McLaughlin, M.S.
Senior Clinical Scientist, eCOA Neuroscience at Clario
Bill McLaughlin is an experienced Clinical Scientist with expertise in the pharmaceutical, biotechnology, and medical device industry. Initially, Bill was involved in nonclinical research in psychophysics, behavior genetics, and neurodegenerative disorders. Switching to clinical research, he started at a CRO and spent most of the rest of his career at various sponsors, primarily doing psychiatric and neurological research, including Alzheimer’s disease, stroke, migraine, & autism spectrum disorder. Within the past few years, Bill has worked at legacy-WCG/Clario on clinical endpoint solutions.